Home › Therapeutic areas › Oncology › Pancreatic Cancer
Pancreatic Cancer (25 companies)
Companies with an active program in Pancreatic Cancer.
| Ticker | Company | Therapeutic areas | Programs | Lead stage | Programs |
|---|---|---|---|---|---|
| ACTU | Actuate Therapeutics | Oncology | 1 | Phase 2 | 4 |
| ALLO | Allogene Therapeutics | ImmunologyOncology Rare | 1 | Phase 2 | 10 |
| DRTS | Alpha Tau Medical | Oncology | 1 | Phase 2 | 6 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 1 | Phase 3 | 6 |
| ARVN | Arvinas | NeurologyOncology Rare | 1 | Approved | 12 |
| BBOT | BridgeBio Oncology Therapeutics | Oncology | 2 | Phase 1 | 6 |
| CLRB | Cellectar Biosciences | Oncology | 1 | Phase 2 | 6 |
| CTMX | CytomX Therapeutics | Oncology | 1 | Phase 1 | 6 |
| EIKN | Eikon Therapeutics | Oncology | 2 | Phase 2 | 13 |
| ELTX | Elicio Therapeutics | Oncology | 2 | Phase 2 | 6 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | 13 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | 5 |
| IBRX | ImmunityBio | Infectious DiseaseOncology | 2 | Approved | 16 |
| KURA | Kura Oncology | MetabolicOncology | 1 | Approved | 12 |
| LEGN | Legend Biotech | Oncology Rare | 1 | Approved | 17 |
| MRKR | Marker Therapeutics | Oncology | 1 | Phase 1 | 4 |
| MBRX | Moleculin Biotech | Oncology | 1 | Phase 2 | 10 |
| NBP | NovaBridge Biosciences | OncologyOphthalmology | 1 | Phase 2 | 6 |
| ONCY | Oncolytics Biotech | Oncology | 1 | Phase 2 | 3 |
| PMVP | PMV Pharmaceuticals | Oncology | 1 | Phase 2 | 7 |
| RVMD | Revolution Medicines | Oncology | 2 | Approved | 10 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | 9 |
| TNGX | Tango Therapeutics | Oncology | 1 | Phase 1 | 4 |
| VSTM | Verastem | Oncology | 2 | Approved | 5 |
| XNCR | Xencor | HematologyImmunology+4 Rare | 1 | Approved | 36 |
No companies match.